secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIGAND PHARMACEUTICALS INC (LGND)
CIK:        0000886163
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0000886163-25-000033
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ligand Q1 revenue up 46% to $45.3M; core adjusted EPS $1.33; reaffirms FY guidance
--------------------------------------------------------------------------------

- Total revenues $45.3M (+46% YoY), royalties $27.5M (+44%), Captisol $13.5M (+47%).
- GAAP net loss $42.5M ($2.21/sh) includes $44.3M one-time R&D charge for Castle Creek; core adjusted net income $26.6M ($1.33/sh).
- Reaffirms FY2025 guidance: revenue $180-200M, adjusted EPS $6.00-$6.25.
- Pelthos to merge with Channel Therapeutics (NYSE: PTHS) backed by $50M capital; expected close summer 2025.
- Led $50M of $75M Castle Creek royalty financing for D-Fi Phase 3; net mid-single digit royalty.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/886163/000088616325000033/0000886163-25-000033-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/886163/000088616325000033/lgnd-20250508.htm
  HTML page:      https://secwatch.observer/filing/0000886163-25-000033

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer